NCT00004744已完成3 期
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 76
研究概览
简要总结
OBJECTIVES: I. Determine whether high-dose intravenous immune globulin (IVIG) is more effective than placebo in restoring neurologic function (muscle strength) in patients with multiple sclerosis.
II. Determine the time to recovery following IVIG.
详细描述
PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are treated with intravenous immune globulin or placebo. In the absence of a hypersensitivity reaction to a test dose, a total of 11 doses is administered: daily for 5 days, then every 2 weeks for 12 weeks.
Patients are followed at 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT00220740Grifols Therapeutics LLC117
已完成
2 期
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic GanglionopathyAutoimmune Autonomic Ganglionopathy (AAG)NCT01522235Beth Israel Deaconess Medical Center6
招募中
4 期
Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in ChildrenNewly Diagnosed Immune Thrombocytopenia in Children, First Line TreatmentNCT05520892Fujian Medical University Union Hospital580
已完成
2 期
High-Dose Intravenous Immunoglobulin to Treat Cerebellar DegenerationSpinocerebellar DegenerationsNCT00034242National Institute of Neurological Disorders and Stroke (NINDS)20
已完成
2 期
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)COVID-19NCT04480424Grifols Therapeutics LLC100